Chemical Hybridization of Glucagon and Thyroid Hormone Optimizes Therapeutic Impact for Metabolic Disease

Finan, Brian, Clemmensen, Christoffer, Zhu, Zhimeng, Stemmer, Kerstin, Gauthier, Karine, Müller, Luisa, De Angelis, Meri, Moreth, Kristin +34 more·2016·Cell
DOI 10.1016/j.cell.2016.09.014

Cited by (190)

Items 101–190 of 190

  1. Dual and Triple Gut Peptide Agonists on the Horizon for the Treatment of Type 2 Diabetes and Obesity. An Overview of Preclinical and Clinical Data
    Ioanna A. Anastasiou, Georgia Argyrakopoulou, Μaria Dalamaga, Alexander D. Kokkinos · 2025 · Current Obesity Reports
  2. Optimization of peptide-based polyagonists for treatment of diabetes and obesity
    Patrick J. Knerr, Brian Finan, Vasily M. Gelfanov, Diego Pérez–Tilve, Matthias H. Tschöp, Richard D. DiMarchi · 2017 · Bioorganic & Medicinal Chemistry
  3. Deletion of the glucagon receptor gene before and after experimental diabetes reveals differential protection from hyperglycemia
    Belén Rivero‐Gutiérrez, April M. Haller, Jenna Holland, Emily Yates, Radha Khrisna, Kirk M. Habegger, Richard D. DiMarchi, David A. D’Alessio, Diego Pérez–Tilve · 2018 · Molecular Metabolism
  4. Metabolic Syndrome in Thyroid Disease
    Karl Alexander Iwen, Rebecca Oelkrug, Hannes Kalscheuer, Georg E. Brabant · 2018 · Frontiers of hormone research
  5. Brown adipocytes local response to thyroid hormone is required for adaptive thermogenesis in adult male mice
    Yanis Zekri, Romain Guyot, Inés Garteizgogeascoa Suñer, Laurence Canaple, Amandine Gautier‐Stein, Justine Vily‐Petit, Denise Aubert, Sabine Richard, Frédéric Flamant, Karine Cécile Gauthier · 2022 · eLife
  6. Why are we still in need for novel anti-obesity medications?
    Aaron Novikoff, Gerald Grandl, Xue Liu, Timo D. Müller · 2024 · The Lancet Regional Health - Europe
  7. Hepatic miR-378 modulates serum cholesterol levels by regulating hepatic bile acid synthesis
    Chao Sun, Wei Liu, Zhiqiang Lu, Yan Li, Shengnan Liu, Zhili Tang, Ying Yan, Zhiyang Li, Hua Feng, Duo Zhang et al. · 2021 · Theranostics
  8. Approved and Emerging Hormone-Based Anti-Obesity Medications: A Review Article
    Wael R. Sidrak, Sanjay Kalra, Atul Kalhan · 2024 · Indian Journal of Endocrinology and Metabolism
  9. Stereochemical inversion as a route to improved biophysical properties of therapeutic peptides exemplified by glucagon
    Piotr A. Mroz, Diego Pérez–Tilve, John P. Mayer, Richard D. DiMarchi · 2018 · Communications Chemistry
  10. Reprint of: Recent Updates on Obesity Treatments: Available Drugs and Future Directions
    Nathalia Romanelli Vicente Dragano, Johan Fernø, Carlos Diéguez, Miguel López, Edward Milbank · 2020 · Neuroscience
  11. Designing poly-agonists for treatment of metabolic diseases: challenges and opportunities
    Petersen, Jonas, Strømgaard, Kristian, Frølund, Bente, Clemmensen, Christoffer · 2019 · Drugs
  12. Weighing in on the role of brown adipose tissue for treatment of obesity
    Brinda Prapaharan, Micah B S Lea, Jacqueline Leah Beaudry · 2024 · Journal of Pharmacy & Pharmaceutical Sciences
  13. Antisense oligonucleotide and thyroid hormone conjugates for obesity treatment
    Yang Cao, Tomoko Matsubara, Can Zhao, Wei Qiang Gao, Linxiu Peng, Jinjun Shan, Zhengxia Liu, Fang Yuan, Lingyi Tang, Pei-Xin Li et al. · 2017 · Scientific Reports
  14. Novel Aspects of White Adipose Tissue Browning by Thyroid Hormones
    Kerstin Krause · 2019 · Experimental and Clinical Endocrinology & Diabetes
  15. The Structural Refinement of Glucagon for Therapeutic Use.
    Joseph R. Chabenne, P. Mroz, J. Mayer, R. DiMarchi · 2019 · Journal of Medicinal Chemistry
  16. Propamocarb exposure has the potential to accelerate the formation of atherosclerosis in both WT and ApoE−/− mice accompanied by gut microbiota dysbiosis
    Cuiyuan Jin, You Zhu Weng, Yi Zhang, Zhiwei Bao, Guiling Yang, Zhengwei Fu, Yuanxiang Jin · 2021 · The Science of The Total Environment
  17. Nuclear hormone and peptide hormone therapeutics for NAFLD and NASH
    Brian Finan, Sebastian Demian Parlee, Bin S. Yang · 2020 · Molecular Metabolism
  18. The thyroid hormone levels and glucose and lipid metabolism in children with type 1 diabetes: a correlation analysis
    Chuanjie Yuan, Xiaomei Sun, Yin Liu, Jin Wu · 2021 · Translational Pediatrics
  19. Poly-Agonist Pharmacotherapies for Metabolic Diseases: Hopes and New Challenges
    C. Allard, Daniela Cota, Carmelo Quarta · 2023 · Drugs
  20. The agony and the efficacy: central mechanisms of GLP-1 induced adverse events and their mitigation by GIP
    Jonathan D. Douros, Jonathan N. Flak, Patrick J. Knerr · 2025 · Frontiers in Endocrinology
  21. Drug discovery approaches targeting the incretin pathway
    Xinxian Deng, Mojdeh S. Tavallaie, Ran Sun, Juntao Wang, Qingqing Cai, Jian Shen, Shuwen Lei, Lei Fu, Faqin Jiang · 2020 · Bioorganic Chemistry
  22. Discovery of a novel, liver-targeted thyroid hormone receptor-β agonist, CS271011, in the treatment of lipid metabolism disorders
    Su-Wen Lin, Shengjian Huang, Zhou Deng, Yu Zhang, Lin Huang, Yanyi Wu, Shuyan Lv, Zhiyi Wang, Ning Huang, Lan Wang et al. · 2023 · Frontiers in Endocrinology
  23. Polyploidisation pleiotropically buffers ageing in hepatocytes
    Kelvin Yin, Maren Büttner, Ioannis K. Deligiannis, Mateusz Strzelecki, Liwei Zhang, Carlos N. Talavera-López, Fabian Joachim Theis, Duncan T. Odom, Celia Pilar Martinez‐Jimenez · 2024 · Journal of Hepatology
  24. 3,5-T2-an Endogenous Thyroid Hormone Metabolite as Promising Lead Substance in Anti-Steatotic Drug Development?
    Rajas Sane, Eva Katrin Wirth, Josef Köhrle · 2022 · Metabolites
  25. Exciting advances in GPCR-based drugs discovery for treating metabolic disease and future perspectives
    Mar Quiñones, Johan Fernø, Carlos Diéguez, Rubén Nogueiras, Omar Al–Massadi · 2019 · Expert Opinion on Drug Discovery
  26. Allan-Herndon-Dudley-Syndrome: Considerations about the Brain Phenotype with Implications for Treatment Strategies
    Heiko Krude, Heike Biebermann, Markus Schuelke, Timo D. Müller, Matthias H. Tschöp · 2020 · Experimental and Clinical Endocrinology & Diabetes
  27. Validation of Mct8/Oatp1c1 dKO mice as a model organism for the Allan-Herndon-Dudley Syndrome
    Gandhari Maity‐Kumar, Lisa Ständer, Meri De Angelis, Sooyeon Lee, Anna Molenaar, Lore Becker, Lillian Garrett, Oana V. Amerie, Sabine M. Hölter, Wolfgang Wurst et al. · 2022 · Molecular Metabolism
  28. Polypharmacy through Phage Display: Selection of Glucagon and GLP-1 Receptor Co-agonists from a Phage-Displayed Peptide Library
    Anna Demartis, Armin Lahm, Licia Tomei, Elisa Beghetto, Valentina Di Biasio, Federica Orvieto, Francesco Frattolillo, Paul E. Carrington, Sheena Mumick, Brian E. Hawes et al. · 2018 · Scientific Reports
  29. The evolving landscape of obesity pharmacotherapy
    Jonas Petersen, Brian Finan, Valdemar Brimnes Ingemann Johansen, Timo D. Müller, Christoffer Clemmensen · 2026 · Nature Reviews Drug Discovery
  30. Glucagon is associated with NAFLD inflammatory progression in type 2 diabetes, not with NAFLD fibrotic progression
    Yuying Wang, Zhiqi Lin, Heng Wan, Wen Zhang, Fangzhen Xia, Yi Chen, Xiaoman Chen, Chiyu Wang, Chi Chen, Ningjian Wang et al. · 2021 · European Journal of Gastroenterology & Hepatology
  31. Novel approaches to anti-obesity drug discovery with gut hormones over the past 10 years
    Frances Rose, Stephen Robert Bloom, Tricia Tan · 2019 · Expert Opinion on Drug Discovery
  32. Maladaptive regeneration and metabolic dysfunction associated steatotic liver disease: Common mechanisms and potential therapeutic targets
    Dandan Wu, Stan F.J. van de Graaf · 2024 · Biochemical Pharmacology
  33. Emerging Poly‐Agonists for Obesity and Type 2 Diabetes
    Maximilian Kleinert, Christoffer Clemmensen, Kerstin Stemmer, Timo D. Müller, Richard D. DiMarchi, Matthias H. Tschöp · 2017 · Obesity
  34. Treatment of obesity-related diabetes: significance of thermogenic adipose tissue and targetable receptors
    Ruping Pan, Jiadai Liu, Yong Chen · 2023 · Frontiers in Pharmacology
  35. Thyroid hormones are required for thermogenesis of beige adipocytes induced by Zfp423 inactivation
    Lisa Giulino Roth, Anne Hoffmann, Tobias Hagemann, Leonie Wagner, Christian Strehlau, Bilal N. Sheikh, Lorenz Donndorf, Adhideb Ghosh, Falko Noé, Christian Wolfrum et al. · 2024 · Cell Reports
  36. Glucagon signaling via supraphysiologic GCGR can reduce cell viability without stimulating gluconeogenic gene expression in liver cancer cells
    Jason T. Godfrey, Romain Riscal, Nicolas Skuli, Marie Celeste Simon · 2022 · Cancer & Metabolism
  37. A Novel Noninvasive Diagnostic Model of HBV-Related Inflammation in Chronic Hepatitis B Virus Infection Patients With Concurrent Nonalcoholic Fatty Liver Disease
    Xuemei Tao, Lin Chen, Youfei Zhao, Yonggang Liu, Ruifang Shi, Bei Jiang, Yuqiang Mi, Liang Xu · 2022 · Frontiers in Medicine
  38. Designing a combined liothyronine (LT3), L- thyroxine (LT4) trial in symptomatic hypothyroid subjects on LT4 - the importance of patient selection, choice of LT3 and trial design
    Premawardhana, Lakdasa D., Taylor, Peter Nicholas, Okosieme, Onyebuchi E., Adlan, Mohamed A., Obuobie, Emmanuel K., Dayan, Colin Mark · 2023 · Frontiers in Endocrinology
  39. Glucagon-modified Liposomes Delivering Thyroid Hormone for Anti-obesity Therapy
    Juan Liu, Xinrui Zhou, Chao Feng, Wenfang Zheng, Pu Chen, Xiaozhi Zhang, Peng Hou · 2023 · Archives of Medical Research
  40. Glucagon and Thyroid Hormone: A Championship Team
    Alan Saghatelian, Ben F. Cravatt · 2016 · Cell
  41. Thyroid hormone Beta receptor agonists for treatment of kidney disease: A promising agent?
    Sidar Çöpür, Furkan Yavuz, Mehmet Kanbay · 2022 · European Journal of Clinical Investigation
  42. Selective polypeptide ligand binding to the extracellular surface of the transmembrane domains of the class B GPCRs GLP-1R and GCGR
    Huixia Wang, Wanhui Hu, Tiandan Xu, Ya Yuan, Dongsheng Liu, Kurt Wüthrich A · 2023 · iScience
  43. Innovative Glucagon-based Therapies for Obesity
    Kibret Enyew Belay, Rebil Heiru Jemal, Aloys Tuyizere · 2024 · Journal of the Endocrine Society
  44. Estrogenic activity of E2-conjugated GLP-1 is mediated by intracellular endolysosomal acidification and estrone metabolism
    Callum Coupland, Na Sun, Ahmed Khalil, Ezgi Karaoglu, Arkadiusz Liśkiewicz, Daniela Liśkiewicz, Gerald Grandl, Seun Akindehin, Gandhari Maity‐Kumar, Bin S. Yang et al. · 2025 · Molecular Metabolism
  45. Hypothalamic control of heart rate and body temperature by thyroid hormones
    Jens Mittag, Beke Kolms · 2025 · Reviews in Endocrine and Metabolic Disorders
  46. Circ_HUWE1: a novel regulator of lipid accumulation, inflammation, and gut microbiota in atherosclerosis
    Zulong Sheng, Yi Fan, Zhenjun Ji, Yanru He, Rui Zhang, Yuyu Yao, Genshan Ma · 2025 · Cell & Bioscience
  47. Glucagon receptor signaling is indispensable for the healthspan effects of caloric restriction in aging male mice
    Kassandra R. Bruner, Isabella R. Byington, Tyler J. Marx, Anastasiia Vasileva, Thea Fletcher, Susma Ghimire, India J. Zappia, Yashika Shaju, Janan Zeng, Hallie R. Wachsmuth et al. · 2025 · GeroScience
  48. Using Single-Cell RNA-Seq Data to Trace Tissue Cells Responsive to Thyroid Hormones
    Liang Hu, Chao Wu · 2021 · Frontiers in Endocrinology
  49. Hormetic effect of triiodothyronine in metabolically healthy obese persons
    Ji Eun Jun, Tae Hyuk Kim, Seung‐Eun Lee, You‐Bin Lee, Jae Hwan Jee, Ji Cheol Bae, Sang‐Man Jin, Kyu Yeon Hur, Jae Hyeon Kim, Sun Wook Kim et al. · 2017 · Endocrine
  50. Drug targets regulate systemic metabolism and provide new horizons to treat nonalcoholic steatohepatitis
    Yibing Wang, Hanhan Yu, Zhipeng Cen, Yutong Zhu, Wenyi Wu · 2023 · Metabolism Open
  51. Scaling it down: new in vitro tools to get the balance right
    Emma K. Biggs, Fiona Mary Gribble, Frank M. Reimann · 2016 · Biochemical Journal
  52. Hybrid peptides in the landscape of drug discovery
    Daniel Fourmy · 2017 · Peptides
  53. Pas de Deux: Glucagon and Thyroid Hormone Moving in Perfect Synchrony.
    Alexandra L. Ghaben, Philipp E. Scherer · 2017 · PubMed
  54. De la découverte des incrétines aux blockbusters coupe-faim. 100 ans de recherches pour arriver sous les feux de l’actualité thérapeutique
    Bernard Portha, Junjun Liu, Jamileh Movassat, Cécile Tourrel‐Cuzin · 2024 · Cahiers de Nutrition et de Diététique
  55. Overnutrition in mice impairs thyroid hormone biosynthesis and utilization, causing hypothyroidism, despite remarkable thyroidal adaptations
    Jessica Rampy, Alejandra Paola Torres-Manzo, Kendra Hoffsmith, Matthew A. Loberg, Quanhu Sheng, Federico Salas-Lucia, Antonio C. Bianco, Rafael Arrojo e Drigo, Huiying Wang, Vivian Lee Weiss et al. · 2026 · Journal of Clinical Investigation
  56. Cross-Talk Between Thyroid Disorders and Nonalcoholic Fatty Liver Disease: From Pathophysiology to Therapeutics
    Yan Yang, Jiyuan Xiao, Wen Qiu, Luxia Jiang · 2024 · Hormone and Metabolic Research
  57. Role of serum fasting glucagon in hypothyroidism-related nonalcoholic fatty liver disease
    Mervat M. El-Eshmawy, Amira F. Barakat, Azza A. El-Baiomy, Mohamed Mosad Abo Elnaga, Mohamed Adel Elbasiony · 2025 · Nutrition & Metabolism
  58. Hypothyroidism, diabetes, and cardiovascular disease
    Margaret L. England, Jon M. Gerrard · 2024 · Elsevier eBooks
  59. Doubles-agonistes, tri-agonistes et multi-agonistes incrétines/glucagon
    Franck Phan, Fabrizio Andréelli · 2021 · Médecine des Maladies Métaboliques
  60. Targeted delivery of thyroid hormone improves metabolic outcomes
    Claire Greenhill · 2016 · Nature Reviews Endocrinology
  61. From incretin discovery to anti-obesity blockbuster drugs. One hundred years of research to move from shadow to spotlight
    Bernard Portha, Junjun Liu, Jamileh Movassat, Cécile Tourrel‐Cuzin · 2025 · Cahiers de Nutrition et de Diététique
  62. Pharmacotherapy in metabolic-dysfunction-associated steatotic liver disease: an updated review of the past, present and a promising future
    Sunetra Mondal, Amarta Shankar Chowdhury, Rajat Deb, Debmalya Sanyal · 2025 · Diabetology International
  63. Ectopic, hepatic GLP-1R agonism enhances the weight loss efficacy of GLP-1 analogues
    Jonathan D. Douros, Megan E. Capozzi, Aaron Novikoff, Jacek Mokrosiński, BARENT N. DUBOIS, Joseph Stock, Rebecca Rohlfs, Mikayla Anderson, Dominika J Jedrzejcyk, Svend Poulsen et al. · 2026 · Molecular Metabolism
  64. The Role of Iron in Adipose Tissue Function, Crosstalk, and Transdifferentiation
    Jiamin Guo, Panpan Yu, 李陈康, 聂桂英, Wenchen Xu, Meiyi Chen, Liang Li, Tianhong Peng, Wei Xie · 2026 · Cell Biochemistry and Function
  65. Hormone conjugate combats metabolic syndrome
    Sarah Crunkhorn · 2016 · Nature Reviews Drug Discovery
  66. Master role of glucose-6-phosphate in cell signaling and consequences of its deregulation in the liver and kidneys
    Fabienne Rajas, Gilles Mithieux · 2019 · Elsevier eBooks
  67. Polypharmakologie als ein neuer Ansatz zur Präzisionsmedizin in der Adipositas- und Diabetestherapie
    Sigrid Jall, A. Götz, M. Tschöp, Timo D. Müller · 2018 · Adipositas - Ursachen Folgeerkrankungen Therapie
  68. New advances and novel approaches in obesity pharmacotherapy
    Javier Gargallo Vaamonde, Gema Frühbeck, Javier Salvador · 2018 · Current Opinion in Endocrine and Metabolic Research
  69. Association of Visceral Fat with Pulmonary Function in Hypothyroidism Patients
    Dr. Harminder Singh · 2021 · Scholars Journal of Applied Medical Sciences
  70. Diabetes: Insights into Thyroid Hormones
    Shahid Shehzad, Muhammad Naeem, Rasif Khan, Rashed Ali Khan, Saqibah Rehman, Rida Naz · 2022 · Pakistan Journal of Medical and Health Sciences
  71. Peptide‐small Molecule Drug Conjugates for Cancer, Metabolic Diseases, and Beyond
    Rongjun He, Sumeet Singh, Adam R. Mezo · 2025 · Peptide Science
  72. Metabolic Syndrome: One Speckled Stone Kills a Flock of Birds?
    Ylva Bonde, Bo Angelin · 2017 · Trends in Molecular Medicine
  73. Einfluss der Fettleber auf den Glukosestoffwechsel nicht unterschätzen
    Norbert Stefan, F Pfeiffer Andreas, Andreas L. Birkenfeld, Stephan Herzig, Annette Schürmann, Matthias H. Tschöp, Hans-Ulrich Häring, Michael Roden · 2017 · Diabetes aktuell
  74. Inkretinbasierte Medikamente zur Diabetes- und Adipositastherapie
    A. Götz, Sigrid Jall, M. Tschöp, Timo D. Müller · 2017 · Der Diabetologe
  75. Le glucagon : le retour du vilain petit canard
    Étienne Larger, Marc Diedisheim, Xavier Donath, C. Tiercelin · 2018 · Médecine des Maladies Métaboliques
  76. Folgeerkrankungen des Diabetes mellitus
    Stephan Herzig, Barbara Thorand, Annette Peters, Dan Ziegler · 2021 · Diabetes aktuell
  77. Design and Characterization of a Fluorescent Reporter Enabling Live-cell Monitoring of MCT8 Expression
    Adina Sophie Graffunder, Sarah Paisdzior, Robert Opitz, Kostja Renko, Peter Kühnen, Heike Biebermann · 2021 · Experimental and Clinical Endocrinology & Diabetes
  78. Faculty Opinions recommendation of Regulation of hepatic glucose metabolism in health and disease.
    Carlos Alberto Aguilar-Salinas · 2019 · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature
  79. GIP receptor agonism improves dyslipidemia and atherosclerosis independently of body weight loss in preclinical mouse model for cardio-metabolic disease
    Stephan Sachs, Anna Götz, Brian Finan, Annette Feuchtinger, Richard D. DiMarchi, Yvonne Döring, Christian Weber, Matthias H. Tschöp, Timo D. Müller, Susanna M. Hofmann · 2023 · Research Square
  80. Knockdown of VAMP8 attenuates atherosclerosis and enhances the effect of simvastatin in APOE-deficient mice
    Lei Zhan, Hua Zhao · 2023 · Tropical Journal of Pharmaceutical Research
  81. Progressive Study on Thyroid Hormones and Adipose Tissue
    蓉 朱 · 2023 · Advances in Clinical Medicine
  82. Evaluation of thyroid hormones in type 1 diabetes mellitus
    Amna Abdullah, Sardar Ahmed · 2024 · Zanco Journal of Medical Sciences
  83. Overnutrition directly impairs thyroid hormone biosynthesis and utilization, causing hypothyroidism, despite remarkable thyroidal adaptations
    Jessica Rampy, Alejandra Paola Torres-Manzo, Kendra Hoffsmith, Matthew A. Loberg, Quanhu Sheng, Federico Salas-Lucia, Antonio Carlos Bianco, Rafael Arrojo e Drigo, Huiying Wang, Vivian Lee Weiss et al. · 2025 · bioRxiv (Cold Spring Harbor Laboratory)
  84. Additional file 1 of Glucagon signaling via supraphysiologic GCGR can reduce cell viability without stimulating gluconeogenic gene expression in liver cancer cells
    Godfrey, Jason, Romain Riscal, Nicolas Skuli, Marie Celeste Simon · 2022 · Figshare
  85. The application of metabolomics by high field nuclear magnetic resonance to study thyroid signalisation pathologies in mice
    Houda Boumaza · 2019 · theses.fr (ABES)
  86. Gènes cibles des hormones thyroïdiennes, un regard nouveau par le prisme des analyses pangénomiques
    Yanis Zekri · 2022 · theses.fr (ABES)
  87. Harnessing PPAR pharmacology through dual incretin-directed delivery
    Jonas Petersen, Christoffer Clemmensen · 2026 · Cell Metabolism
  88. Thyroid-Liver Axis: Mechanistic Insights and Clinical Implications
    Naima Parveen, Sachin Chittawar, Deepak Khandelwal, Sameer Aggarwal · 2026 · Cureus
  89. Histoire des incrétines GLP-1/GIP – De l’hormone au médicament couteau-suisse
    Bernard Portha · 2026 · Biologie Aujourd hui
  90. BindingDB Entry 50002557: Optimization of peptide-based polyagonists for treatment of diabetes and obesity.
    BindingDB · 2020 · UC San Diego